Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma
- Facial Paralysis Prevention study initiated and first patient enrolled evaluating the safety and efficacy of NTX-001 following facial nerve surgery - Ongoing Trauma Phase 2 study hits enrollment milestone with topline data expected in 2nd half of 2023 Neurap